{"product_id":"diasoringroup-marketing-mix","title":"DiaSorin Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how DiaSorin’s product innovation, pricing architecture, distribution channels, and promotion mix combine to strengthen its position in diagnostics—this concise preview highlights key patterns driving market success.\u003c\/p\u003e\n\u003cp\u003eWant the complete, editable 4Ps Marketing Mix Analysis with real-world data, strategic insights, and ready-to-use slides for reports or presentations? Purchase the full report to save hours and apply a proven framework tailored to DiaSorin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Immunoassay Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin’s Automated Immunoassay Platforms use the LIAISON XL and XS analyzers to deliver high-throughput automation, processing up to 200 tests\/hour on XL and 60 tests\/hour on XS, reducing hands-on time by ~40% in large labs.\u003c\/p\u003e\n\u003cp\u003eDesigned to cut manual steps and improve accuracy, the platforms report analytical CVs under 5% for key assays, supporting routine and specialty diagnostics across 2,500+ installed sites globally.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 DiaSorin is prioritizing middleware integration—projected to reduce turnaround time by 20% and lower error rates—while targeting a 5–7% revenue uplift from connected solutions in FY2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Diagnostic Assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin holds a leading share in specialty testing—about 40% global share in bone\/mineral and endocrine niche markets in 2024—driven by proprietary assays for Vitamin D and autoimmune markers that generate higher margins than routine tests.\u003c\/p\u003e\n\u003cp\u003eTheir menu of 70+ specialty assays helps clinicians diagnose complex conditions (eg, Vitamin D deficiency, thyroid and autoimmune disorders), supporting service revenues that grew 8% YoY to €1.2bn in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular Diagnostic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing the 2022 Luminex integration, DiaSorin’s molecular portfolio — notably Verigene and xMAP platforms — delivers multiplex detection of infectious agents and genetic markers from one sample, cutting time-to-result to 2–6 hours and serving \u0026gt;1,200 hospital labs by 2025; molecular sales grew 18% YoY to €190m in FY2024, making these solutions a core revenue driver and clinical-decison tool across epidemiology and oncology workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed Technology Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiaSorin’s Licensed Technologies Group sells xMAP-based beads and tech to life-science firms, supporting genomic and proteomic research and extending beyond finished IVD kits.\u003c\/p\u003e\n\u003cp\u003eThis B2B arm contributed about €48m in 2024 revenue (roughly 6% of group sales), creating a steady secondary cash flow and boosting DiaSorin’s role as a platform provider.\u003c\/p\u003e\n\u003cp\u003eLicensing strengthens partnerships, increases platform stickiness, and offsets diagnostic cyclicality, supporting recurring consumables demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 licensed tech revenue: ~€48m\u003c\/li\u003e\n\u003cli\u003eContribution to group sales: ~6%\u003c\/li\u003e\n\u003cli\u003eCore tech: xMAP beads for genomics\/proteomics\u003c\/li\u003e\n\u003cli\u003eBenefit: recurring consumables and partner lock‑in\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumables and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe product line centers on high-quality reagent kits and consumables for DiaSorin’s installed analyzers, driving recurring revenue—consumables made up about 62% of DiaSorin's 2024 reagent segment sales of €730m (pro forma).\u003c\/p\u003e\n\u003cp\u003eReagents are engineered for high sensitivity and specificity, supporting reliable clinical outcomes and reducing false positives; DiaSorin reports clinical sensitivity \u0026gt;98% on key assays in 2024 validation data.\u003c\/p\u003e\n\u003cp\u003eOngoing innovation in reagent formulation targets emerging threats—R\u0026amp;D spend was €97m in 2024—to shorten time-to-market for new assays and protect market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsumables = recurring revenue, ~62% of reagent sales (€730m, 2024)\u003c\/li\u003e\n\u003cli\u003eClinical sensitivity \u0026gt;98% on core assays (2024 validations)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D €97m in 2024 to accelerate new assay launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin drives recurring revenue with consumables, R\u0026amp;D-led sensitivity and faster TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin’s product suite centers on LIAISON XL\/XS (200\/60 tests\/hr), 70+ specialty assays, and xMAP\/molecular platforms; consumables drove recurring revenue (62% of €730m reagent sales, 2024) while licensed tech added ~€48m (6% of group). R\u0026amp;D €97m (2024) supports \u0026gt;98% sensitivity claims; middleware integration aims for 20% faster TAT and 5–7% FY2025 revenue uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent sales\u003c\/td\u003e\n\u003ctd\u003e€730m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed tech\u003c\/td\u003e\n\u003ctd\u003e€48m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€97m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular sales\u003c\/td\u003e\n\u003ctd\u003e€190m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into DiaSorin’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for managers, consultants, and marketers seeking a clear benchmarking and strategic toolkit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses DiaSorin's 4P marketing insights into a concise, at-a-glance summary that eases executive briefings and cross-team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin maintains a direct sales and service force across North America, Europe and select Asian markets, supporting ~60% of its reagent revenue regions directly as of FY 2024, which strengthens ties with major hospital networks and large commercial labs.\u003c\/p\u003e\n\u003cp\u003eControlling distribution in these areas lets DiaSorin enforce service SLAs, support a median response time under 24 hours for critical technical calls in 2024, and sustain higher attachment rates for assays versus indirect channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin uses a hybrid distribution model: direct sales in core markets and specialized third-party distributors in emerging regions, covering over 120 countries as of 2025.\u003c\/p\u003e\n\u003cp\u003ePartners are chosen for local market expertise and regulatory navigation; roughly 40% of international revenue in 2024 came via distributors, per company disclosures.\u003c\/p\u003e\n\u003cp\u003eThis network helped DiaSorin reach ~$1.3 billion in 2024 sales, keeping time-to-market faster and regulatory costs lower in complex jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Laboratory Placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin places LIAISON analyzers in high-volume hospitals and private diagnostic centers to capture regional hubs; in 2024 these sites accounted for roughly 62% of reagent sales, per company reports.\u003c\/p\u003e\n\u003cp\u003eBy making LIAISON the primary local platform, DiaSorin secures recurring demand for proprietary reagents and consumables, supporting a consumables-driven revenue mix—about €360M in 2024 consumables sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Logistics Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiaSorin operates manufacturing and logistics hubs in Italy, the United States, and other strategic sites, supporting a resilient global supply chain that cut average lead times by ~18% in 2024.\u003c\/p\u003e\n\u003cp\u003eThese hubs lower transport costs for temperature-sensitive diagnostics via regional cold-chain networks, helping maintain service levels during peak demand and preserving product integrity.\u003c\/p\u003e\n\u003cp\u003eInventory optimization at these sites kept on-hand availability above 95% in 2024, limiting stockouts amid surges in test demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocations: Italy, USA, other strategic sites\u003c\/li\u003e\n\u003cli\u003eLead-time reduction: ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eOn-hand availability: \u0026gt;95% (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: cold-chain logistics, inventory optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoint of Care Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiaSorin has expanded point-of-care (POC) diagnostics into decentralized clinics and physician offices, increasing POC revenue share to about 18% of 2024 group sales (€331m POC vs €1.84bn total in FY2024) and cutting average turnaround time from days to minutes for key assays.\u003c\/p\u003e\n\u003cp\u003eThis move meets rising demand: 62% of clinicians surveyed in 2024 preferred on-site rapid testing for respiratory and cardiac markers, boosting DiaSorin’s POC order volumes by ~24% YoY in H2 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e18% of 2024 sales from POC (€331m)\u003c\/li\u003e\n\u003cli\u003e24% YoY POC order growth H2 2024\u003c\/li\u003e\n\u003cli\u003e62% clinician preference for on-site tests (2024 survey)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin ups POC to €331m, 18% share; 95%+ availability and 18% shorter lead times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin pairs direct sales in core markets with distributors in 120+ countries (2025), supporting ~60% reagent revenue directly (FY2024), \u0026gt;95% on-hand availability and ~18% lead-time cut (2024); POC grew to 18% of sales (€331m) with 24% YoY H2 2024 order growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect coverage\u003c\/td\u003e\n\u003ctd\u003e~60% reagent revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e120+ countries (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-hand availability\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time reduction\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOC share\u003c\/td\u003e\n\u003ctd\u003e18% (€331m, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOC growth\u003c\/td\u003e\n\u003ctd\u003e+24% YoY H2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDiaSorin 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual DiaSorin 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750650720633,"sku":"diasoringroup-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/diasoringroup-marketing-mix.png?v=1772225704","url":"https:\/\/matrixbcg.com\/products\/diasoringroup-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}